Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

13 Dec 2017

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heat shock proteins research
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 29247830
DOI: 10.1016/j.jtho.2017.11.131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung CancerPMID 29247830Read ↗

Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

HSP90 and the cancer transcriptome: a comprehensive review of inhibitors and mechanistic insightsSemantic proximity Read ↗

HSP90 inhibitors in lung cancer: promise still unfulfilled.Semantic proximity Read ↗

HSP90: A promising target for NSCLC treatments.Semantic proximity Read ↗

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Semantic proximity Read ↗

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.Semantic proximity Read ↗

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.Semantic proximity Read ↗

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).Semantic proximity Read ↗

Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.Semantic proximity Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.